Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For MAIN period (NN1250-3582):~* Type 2 diabetes mellitus for at least 6 months~* Ongoing daily treatment with insulin (premix, self-mix, basal only, basal bolus) for at least 3 months with/without oral anti-diabetics drug (OAD) prior to trial start~* HbA1c 7.0-10.0 % (both inclusive)~* Body Mass Index (BMI) below or equal to 40.0 kg/m\^2~* For EXTENSION period (NN1250-3667):~* Completion of the 52 week treatment period in NN1250-3582~Exclusion Criteria:~* For MAIN period (NN1250-3582):~* Treatment with other insulin regimens than premix, self-mix, basal only, basal bolus within 3 months~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures~* Cancer and medical history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).